研究组长
蓝佳明
姓名:蓝佳明
性别:
学历:博士研究生
学科类别:病毒学
人才类别:研究员
联系电话:86-21-54923061
专家类别:
电子邮箱:jmlan@siii.cas.cn
所属部门:新发传染病疫苗和药物研究组
通讯地址:上海市徐汇区岳阳路320号生命科学实验楼
个人简介

  蓝佳明研究员从事病毒性疫苗的研发工作近20年,硕士阶段主要从事人乳头瘤病毒(HPV)核酸疫苗的研究;工作后开展了肠道病毒(CVB3) 病毒载体疫苗和蛋白疫苗的研究。攻读博士学位期间,主要从事中东呼吸综合征病毒(MERS-CoV)的重组蛋白疫苗、病毒载体疫苗以及病毒样颗粒疫苗的研发工作, 于全球首次报告MERS-CoV重组亚单位疫苗在恒河猴模型中的免疫与攻毒保护评价,为冠状疫苗研发应用提供了新思路与技术支撑。入职中国科学院上海巴斯德研究所后主要从事生物安全四级病毒尼帕病毒(Nipah Virus)、埃博拉病毒(Ebola Virus)、生物安全三级病毒新型冠状病毒(SARS-CoV-2)、克里米亚-刚果出血热病毒(Crimean–Congo Hemorrhagic Fever Virus)核酸疫苗、蛋白疫苗和病毒载体疫苗的研发。多年的科研工作经历,始终保持对感染与免疫领域前沿研究的高度敏感,培养了理性的科研思维和浓厚的科研兴趣。目前,已在国内外专业期刊《npj Vaccines》、《JCI INSIGHT》、《J. Immunol.》、《J INFECTION》、《EBIOMEDICINE》、《VACCINE》、《Emerging Microbes Infect.》、《VIROL SIN》发表多篇学术论文;作为第一完成人或主要参与人申请国家专利7项目,其中1项已成功转化;作为主研人获得省级科技进步奖1项;作为课题负责人承担了国家自然科学基金面上项目和青年项目、上海市自然科学基金面上项目和“科技创新行动计划” 实验动物研究专项项目、徐汇区新型冠状病毒诊断与治疗创新产品研发与转化项目,作为主研人参与了中科院先导计划、国家传染病重大专项、国家重点研发项目等。

研究方向

  主要从事病毒性疫苗、抗体和抗病毒药物的研发。关注的病毒包括中东呼吸综合征冠状病毒、新型冠状病毒、克里米亚-刚果出血热病毒、猴痘病毒、尼帕病毒、埃博拉病毒等。  

      代表论文: 

    1.Lu M#, Yao Y#,* , Zhang X, Liu H, Zhang X, Li X, Liu Y, Peng Y, Chen T, Sun Y, Gao G, Chen M, Zhao J, Zhang X, Yin C, Guo W Yang P, Hu X, Rao J, Li E, Wong G, Yuan Z*, Chiu S *,Shan C*,Lan J* (2023).Vaccines based on consensus sequence of the Fusion protein completely protected the Syrian hamsters against Nipah virus infection of Malaysia and Bangladesh strains. JCI insight, Minor revision (*Co-corresponding author)

  2.Lu M#, Yao Y#, *, Zhang X, Liu H, Gao G, Peng Y, Chen M, Zhao J, Zhang X, Yin C, Guo W,2, Yang P, Hu X, Rao J, Li E, Chen T, Chiu S, Gary Wong, Yuan Z*, Lan J*, Shan C*(2023). Both chimpanzee adenovirus-based and DNA vaccines induced long-term immunity against Nipah virus infection. NPJ Vaccine, Accepted, (*Co-corresponding author)

  3.Sun K#, Ding Z#, Jia X#, Cheng H#, Li Y, Wu Y, Li Z, Huang X, Pu F, Li E, Wang G, Wang W, Ding Y, Gary Wong, Chiu S*, Lan J*, Hu A*(2023). Extracellular Disintegration of Viral Proteins as an Innovative Strategy for Developing Broad-Spectrum Antivirals Against Coronavirus. CCS Chem, 5:1–11. (*Co-corresponding author)

  4.Lu M#, Liu K#, Peng Y#, Ding Z#, Li Y, Alexander T, Hu X, Gao G, Guo W, Liu H, Rao J, Zhao J, Chen M, Yuan Z, Wong G*, Shan C*, Yao Y*, Lan J*(2022). Recombinant chimpanzee adenovirus vector vaccine expressing the spike protein provides effective and lasting protection against SARS-CoV-2 infection in mice. Virol Sin, 37(4):581-590. (*Co-corresponding author)

  5.Shen L#, Li S#, Zhu Y#, Zhao J#, Tang X#, Li H, Xing H, Lu M, Frederick C, Huang C, Wong G*, Wang C*, Lan J*(2020). Clinical and Laboratory-Derived Parameters of 119 Hospitalized Patients with Coronavirus Disease 2019 in Xiangyang, Hubei Province, China. J Infect, pii: S0163-453(20)30166-3. (*Co-corresponding author)

  6.Shen L#, Wang C#, Zhao J#, Tang X#, Shen Y#, Lu M, Ding Z, Huang C, Zhang J, Li S, Lan J*, Wong G*, Zhu Y*(2020). Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression. Emerg Microbes Infect, 9(1):1096-1101. (*Co-corresponding author)

  7.Kuo S, Lan J*(2020). Progress on Research Tools of Coronaviruses. Chinese Journal of Virology, 2020 (02): 306–313. (*Corresponding Author).

  8.Yang R#, Lan J#, Huang B, A R, Lu M, Wang W, Wang W, Li W, Deng Y*, Wong G*, Tan W*(2020). Lack of antibody-mediated cross-protection between SARS-CoV-2 and SARS-CoV infections. EBioMedicine, 58:102890. (#Co-First Author).

  9.Lan J#, Deng Y, Song J, Huang B, Wang W, Tan W*(2018). Significant Spike-Specific IgG and Neutralizing Antibodies in Mice Induced by a Novel Chimeric Virus-Like Particle Vaccine Candidate for Middle East Respiratory Syndrome Coronavirus. Virol Sin, 33(5):453-455. (First Author).

  10.Deng Y#, Lan J#, Bao L#, Huang B, Ye F, Chen Y, Yao Y, Wang W, Qin C, Tan W*(2018). Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus. Emerg Microbes Infect, 7(1):60. (#Co-First Author).

  11.Lan J#, Yao Y#, Deng Y#, Hu Y, Bao L, Huang B, Yan J, Gao GF, Qin C, Tan W*(2017). The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Vaccine, 35(1):10-18. (#Co-First Author).

  12.Liu WJ#, Lan J#, Liu K#, Deng Y#, Yao Y#, Wu S, Chen H, Bao L, Zhang H, Zhao M, Wang Q, Han L, Chai Y, Qi J, Zhao J, Meng S, Qin C, Gao GF*, Tan W*(2017). Protective T Cell Responses Featured by Concordant Recognition of Middle East Respiratory Syndrome Coronavirus-Derived CD8+ T Cell Epitopes and Host MHC.J Immuno, 198(2):873-882. (#Co-First Author).

  13.Lan J#, Yao Y#, Deng Y#, Chen H, Lu G, Wang W, Bao L, Deng W, Wei Q, Gao GF, Qin C*, Tan W*(2015). Recombinant Receptor Binding Domain Protein induces Partial Protective Immunity in Rhesus Macaques against Middle East Respiratory Syndrome Coronavirus Challenge. EBioMedicine,2(10):1438-1446. (#Co-First Author).